Early prediction of tumor response to treatment: clinical translation of [99MTC]-duramycin
Ended Project Grant Awarded Last action
- Award ID
- R01CA226531
- Recipient
-
Molecular Targeting Technologies, Inc. UEI Y2FNW7N1V267
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,074,843
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date
- Originally
- Funding
-
- $3,560,455.79 Federal
- $514,387.00 Non-federal
- Place of performance
- Pennsylvania, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$86,172 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $40,895 | $0 | |
| Amendment | $40,895 | $0 | |
| Amendment | $460,068 | $0 | |
| Amendment | $460,068 | $0 | |
| Amendment | $460,068 | $0 | |
| Amendment | $514,387 | $0 | |
| Amendment | $514,387 | $514,387 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $570,747 | $0 | |
| Original award | $585,113 | $0 |
Show all 16
Quick answers
Who received award R01CA226531?
R01CA226531 was awarded to Molecular Targeting Technologies, Inc. by National Cancer Institute (National Institutes of Health) on February 1, 2019.
How much is award R01CA226531 worth?
$4,074,843 has been obligated on R01CA226531: $3,560,456 in federal funding and $514,387 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award